Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Business Wire - Tue Jun 23, 4:10AM CDT

MAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection ...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Business Wire - Thu Jun 18, 6:00AM CDT

Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference Business Wire - Thu May 28, 6:00AM CDT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot AP - Mon May 11, 3:07PM CDT

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 Business Wire - Mon May 11, 3:01PM CDT

Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 ...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 Business Wire - Mon May 4, 6:00AM CDT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Business Wire - Mon Apr 13, 6:00AM CDT

Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 Business Wire - Tue Apr 7, 6:00AM CDT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) Business Wire - Mon Mar 30, 6:00AM CDT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.70 (-3.86%)
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference Business Wire - Tue Mar 3, 6:00AM CST

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.70 (-3.86%)

Barchart Exclusives

Intel Future Price Hikes Send Huge Demand Signal to Wall Street Barchart - Sat Jul 11, 2:30PM CDT
Intel is raising chip prices as server CPU demand outpaces supply, and Wall Street sees the move as proof of a much bigger AI-driven boom ahead. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.